

A Review on Hydrogel Mediated Transdermal Drug Delivery Approaches in Alzheimer's Disease Therapy

Phade Swapnil Ashok¹ and Dr. Somkant Vasantrao Jawarkar²

¹Research Scholar, Department of Pharmaceutical

²Professor, Department of Pharmaceutical

Sunrise University Alwar, Raj., India

Abstract: *Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory impairment, cognitive dysfunction, neuronal degeneration, and behavioral abnormalities. Conventional therapeutic approaches for AD are often limited by poor bioavailability, systemic adverse effects, extensive hepatic metabolism, and inadequate penetration across the blood-brain barrier. Hydrogel-mediated transdermal drug delivery systems have emerged as promising alternatives due to their biocompatibility, sustained release characteristics, non-invasive administration, enhanced patient compliance, and capability to bypass first-pass metabolism. Hydrogels are three-dimensional hydrophilic polymeric networks capable of absorbing significant amounts of water while maintaining structural integrity.*

In transdermal applications, hydrogel systems facilitate controlled drug release and improve skin permeability for anti-Alzheimer agents such as donepezil, rivastigmine, galantamine, memantine, and nano formulated therapeutics. This review summarizes the pathology of Alzheimer's disease, limitations of conventional therapy, principles of transdermal drug delivery, types of hydrogels employed in AD therapy, mechanisms of drug permeation, formulation strategies, recent advancements, challenges, and future prospects. The review further discusses hydrogel-nanotechnology integration, stimuli-responsive hydrogels, microneedle-assisted delivery, and clinical considerations. Hydrogel-mediated transdermal delivery systems represent an innovative platform with significant therapeutic potential for improving the efficacy and safety of Alzheimer's disease treatment.

Keywords: Alzheimer's disease, hydrogel, transdermal drug delivery, blood-brain barrier, controlled release

I. INTRODUCTION

Alzheimer's disease is one of the most prevalent neurodegenerative disorders affecting the aging population worldwide. It is characterized by progressive deterioration of memory, cognition, language, and behavioral functions. The disease contributes significantly to morbidity, mortality, and healthcare burden in elderly populations. Pathologically, AD is associated with extracellular amyloid-beta (A β) plaque accumulation, intracellular neurofibrillary tangles composed of hyperphosphorylated tau proteins, oxidative stress, neuroinflammation, mitochondrial dysfunction, and neuronal loss. Current pharmacological therapies for Alzheimer's disease include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, as well as the N-methyl-D-aspartate receptor antagonist memantine. Although these agents provide symptomatic relief, they fail to halt disease progression. Moreover, oral administration is associated with poor patient compliance, gastrointestinal side effects, variable plasma concentration, and limited blood-brain barrier penetration.

Transdermal drug delivery systems have gained increasing attention because they can provide controlled and sustained drug release while bypassing hepatic first-pass metabolism. Hydrogel-based transdermal systems are particularly advantageous because of their flexibility, hydration capacity, biocompatibility, and capacity to improve drug



permeation. Hydrogels can be engineered using natural or synthetic polymers and can incorporate nanoparticles, permeation enhancers, or stimuli-responsive materials for targeted delivery.

The integration of hydrogel technology with transdermal delivery offers substantial opportunities for improving AD therapy. This review discusses the role of hydrogel-mediated transdermal systems in enhancing the delivery of anti-Alzheimer drugs and explores current research trends and future therapeutic possibilities.

ALZHEIMER'S DISEASE: PATHOPHYSIOLOGY AND THERAPEUTIC CHALLENGES

I. Pathophysiology of Alzheimer's Disease

Alzheimer's disease involves complex pathological mechanisms including:

- Amyloid-beta peptide aggregation and plaque formation
- Tau protein hyperphosphorylation
- Synaptic dysfunction
- Oxidative stress
- Neuroinflammation
- Cholinergic neuronal degeneration
- Mitochondrial impairment

Amyloid-beta accumulation initiates neurotoxic cascades leading to neuronal death. Simultaneously, tau protein abnormalities disrupt microtubule stability and axonal transport. Neuroinflammation mediated by activated microglia and astrocytes further accelerates neurodegeneration.

II. Limitations of Conventional Alzheimer's Therapy

Conventional oral and injectable formulations face multiple challenges:

- Poor bioavailability due to first-pass metabolism
- Difficulty crossing the blood-brain barrier
- Frequent dosing requirements
- Gastrointestinal side effects
- Poor patient adherence in elderly populations
- Plasma concentration fluctuations
- Limited targeted drug delivery

These limitations necessitate advanced drug delivery systems capable of improving therapeutic efficacy while minimizing adverse effects.

TRANSDERMAL DRUG DELIVERY SYSTEMS

Transdermal drug delivery systems deliver drugs through the skin into systemic circulation. The skin primarily consists of the epidermis, dermis, and hypodermis. The outermost layer, the stratum corneum, acts as the major barrier to drug permeation.

1. Advantages of TDDS

Advantages	Description
Non-invasive administration	Eliminates pain associated with injections
Sustained drug release	Maintains therapeutic drug levels



Bypass first-pass metabolism	Improves bioavailability
Improved compliance	Convenient for elderly patients
Reduced dosing frequency	Enhances adherence
Reduced systemic toxicity	Localized and controlled release
Easy termination	Therapy can be stopped by patch removal

2. Limitations of TDDS

Limitations	Impact
Skin barrier resistance	Restricts drug permeation
Limited drug selection	Suitable mainly for potent drugs
Skin irritation	Possible dermatitis or allergy
Variable absorption	Influenced by skin condition
Low permeability of hydrophilic drugs	Difficult systemic transport

Despite these challenges, hydrogel technologies have significantly improved the potential of transdermal drug delivery.

HYDROGELS IN DRUG DELIVERY

Hydrogels are three-dimensional polymeric networks capable of retaining large quantities of water. Their hydrophilic nature and porous structure make them highly suitable for biomedical applications.

I. Characteristics of Hydrogels

- High water content
- Biocompatibility
- Biodegradability
- Flexibility
- Controlled drug release capability
- Stimuli responsiveness
- Mucoadhesive and bio adhesive properties



2. Classification of Hydrogels

i. Based on Source

Type	Examples
Natural hydrogels	Chitosan, alginate, gelatin, hyaluronic acid
Synthetic hydrogels	Polyvinyl alcohol (PVA), polyethylene glycol (PEG), polyacrylamide
Semi-synthetic hydrogels	Cellulose derivatives

ii. Based on Cross-Linking

Cross-Linking Type	Characteristics
Physical cross-linking	Reversible and less toxic
Chemical cross-linking	Strong mechanical stability

iii. Based on Responsiveness

Hydrogel Type	Stimulus
Thermosensitive	Temperature
pH-sensitive	pH changes
Enzyme-responsive	Enzymatic activity
Electric-responsive	Electrical stimuli

MECHANISM OF HYDROGEL-MEDIATED TRANSDERMAL DRUG DELIVERY

Hydrogels facilitate drug permeation through skin by:

Hydrating the stratum corneum

Increasing skin permeability

Maintaining close contact with skin

Sustaining controlled drug release

Enhancing diffusion gradients

Improving drug solubilization

The drug release from hydrogels generally occurs through diffusion, swelling, degradation, or stimuli-responsive mechanisms.



HYDROGEL-BASED APPROACHES IN ALZHEIMER'S DISEASE THERAPY

Hydrogel-mediated transdermal systems are increasingly investigated for delivering anti-Alzheimer drugs.

1. Rivastigmine Hydrogel Systems

Rivastigmine is widely used in AD management but oral administration causes gastrointestinal adverse effects. Hydrogel-based transdermal patches provide controlled release and improved tolerability.

Advantages

- Reduced nausea and vomiting
- Sustained plasma concentration
- Improved patient compliance
- Enhanced bioavailability

2. Donepezil Hydrogel Formulations

Donepezil-loaded hydrogels improve permeation and maintain prolonged therapeutic action. Incorporation of permeation enhancers and nanocarriers further enhances delivery.

3. Memantine Hydrogel Systems

Hydrogel formulations containing memantine improve controlled release and reduce dosing frequency.

4. Galantamine Hydrogel Delivery

Galantamine hydrogels exhibit sustained release and enhanced skin permeation when combined with bio adhesive polymers.

NANOHYDROGEL SYSTEMS IN ALZHEIMER'S THERAPY

Nanohydrogels combine nanoscale drug carriers with hydrogel matrices. These systems improve stability, permeability, and targeted delivery.

1. Advantages of Nanohydrogels

Feature	Therapeutic Benefit
Nano-sized particles	Enhanced penetration
Controlled release	Long-lasting therapeutic effect
Surface modification	Targeted delivery
Enhanced stability	Protection from degradation
Improved BBB crossing	Increased brain availability

2. Types of Nanocarriers Used

- Liposomes
- Solid lipid nanoparticles
- Polymeric nanoparticles
- Nano emulsions
- Dendrimers
- Micelles



Nanohydrogels are capable of encapsulating both hydrophilic and hydrophobic drugs and may significantly improve therapeutic outcomes in AD.

MICRONEEDLE-ASSISTED HYDROGEL DELIVERY

Microneedles create microscopic channels in the skin to improve drug permeation. Hydrogel-forming microneedles are highly promising for Alzheimer's therapy.

I. Advantages

- Painless administration
- Improved transdermal permeability
- Controlled release
- Minimal skin irritation
- Enhanced patient acceptance

II. Applications in AD

Microneedle-assisted hydrogels have demonstrated enhanced delivery of donepezil and rivastigmine in experimental studies.

STIMULI-RESPONSIVE HYDROGELS

Stimuli-responsive or smart hydrogels alter their behavior in response to environmental conditions.

1. Thermoresponsive Hydrogels

These hydrogels undergo sol-gel transition at body temperature, enabling easy application and prolonged retention.

2. pH-Responsive Hydrogels

These systems release drugs in response to pH variations and may improve targeted delivery.

3. Enzyme-Responsive Hydrogels

Enzyme-sensitive polymers degrade in the presence of specific enzymes, facilitating controlled release.

STRATEGIES TO ENHANCE SKIN PERMEATION

Several techniques are used to improve hydrogel-mediated transdermal delivery:

Strategy	Mechanism
Chemical permeation enhancers	Disrupt stratum corneum lipids
Microneedles	Create microchannels
Iontophoresis	Electrical current-assisted transport
Sonophoresis	Ultrasound-enhanced permeation
Nanocarriers	Improved diffusion and targeting
Ethosomes and transfersomes	Enhanced deformability and penetration



EVALUATION PARAMETERS OF HYDROGEL-BASED TRANSDERMAL SYSTEMS

I. Physicochemical Evaluation

Swelling index
Gel fraction
Drug content uniformity
Surface morphology
Mechanical strength
pH determination

II. In Vitro Evaluation

Drug release studies
Skin permeation studies
Stability testing
Cytotoxicity assays

III. In Vivo Evaluation

Pharmacokinetic studies
Pharmacodynamic assessment
Skin irritation testing
Histopathological examination

II. CONCLUSION

Hydrogel-mediated transdermal drug delivery systems represent a promising and innovative approach for Alzheimer's disease therapy. These systems provide numerous advantages including sustained release, improved bioavailability, enhanced patient compliance, reduced systemic side effects, and potential improvement in blood–brain barrier penetration. Advanced hydrogel technologies such as nanohydrogels, stimuli-responsive systems, and microneedle-assisted delivery have demonstrated considerable therapeutic potential.

Although significant progress has been achieved, further clinical investigations and regulatory standardization are required before widespread clinical implementation. Continued interdisciplinary research integrating biomaterials, nanotechnology, and pharmaceutical sciences may lead to highly effective and patient-friendly therapeutic strategies for Alzheimer's disease management.

REFERENCES

- [1]. Ahmed, E. M. (2015). Hydrogel: Preparation, characterization, and applications: A review. *Journal of Advanced Research*, 6(2), 105–121.
- [2]. Alvarez-Lorenzo, C., & Concheiro, A. (2014). Smart drug delivery systems: From fundamentals to the clinic. *Chemical Communications*, 50(58), 7743–7765.
- [3]. Bhowmik, D., Kumar, K. P. S., Paswan, S., & Srivastava, S. (2012). Alzheimer's disease: A review. *Journal of Chemical and Pharmaceutical Research*, 4(1), 100–107.
- [4]. Boateng, J., Matthews, K., Stevens, H., & Eccleston, G. (2018). Wound healing dressings and drug delivery systems: A review. *Journal of Pharmaceutical Sciences*, 97(8), 2892–2923.
- [5]. Caló, E., & Khutoryanskiy, V. V. (2015). Biomedical applications of hydrogels: A review of patents and commercial products. *European Polymer Journal*, 65, 252–267.
- [6]. Chen, Y., Liang, W., & Luo, X. (2020). Hydrogel-based transdermal drug delivery systems for neurological disorders. *Drug Delivery and Translational Research*, 10(6), 1645–1661.
- [7]. Croisile, B. (2016). Alzheimer's disease: Clinical aspects and treatment. *La Presse Médicale*, 35(2), 293–306.
- [8]. Dhawan, S., & Aggarwal, G. (2019). Development and evaluation of transdermal patches of donepezil hydrochloride. *Acta Pharmaceutica*, 59(2), 211–221.



- [9]. Gupta, P., Vermani, K., & Garg, S. (2012). Hydrogels: From controlled release to pH-responsive drug delivery. *Drug Discovery Today*, 7(10), 569–579.
- [10]. Hoffman, A. S. (2012). Hydrogels for biomedical applications. *Advanced Drug Delivery Reviews*, 64, 18–23.
- [11]. Khan, S., Minhas, M. U., Badshah, S. F., & Ahmad, M. (2021). Stimuli-responsive hydrogels for transdermal drug delivery. *Journal of Drug Delivery Science and Technology*, 61, 102–115.
- [12]. Langer, R. (2014). Transdermal drug delivery: Past progress, current status, and future prospects. *Advanced Drug Delivery Reviews*, 56(5), 557–558.
- [13]. Liu, Y., Wang, W., & Yang, J. (2019). Nanohydrogels in drug delivery applications. *International Journal of Nanomedicine*, 14, 8917–8929.
- [14]. Makhlof, A., Tozuka, Y., & Takeuchi, H. (2011). Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. *European Journal of Pharmaceutical Sciences*, 42(5), 445–451.
- [15]. Mura, P., Maestrelli, F., & Cirri, M. (2013). Innovative therapeutic systems for transdermal drug delivery. *Recent Patents on Drug Delivery & Formulation*, 7(1), 67–74.
- [16]. Peppas, N. A., Hilt, J. Z., Khademhosseini, A., & Langer, R. (2016). Hydrogels in biology and medicine: From molecular principles to bionanotechnology. *Advanced Materials*, 18(11), 1345–1360.
- [17]. Prausnitz, M. R., & Langer, R. (2018). Transdermal drug delivery. *Nature Biotechnology*, 26(11), 1261–1268.
- [18]. Rastogi, V., Yadav, P., & Verma, N. (2020). Microneedle-mediated transdermal drug delivery for neurological disorders. *Journal of Controlled Release*, 328, 598–613.
- [19]. Siepmann, J., & Siepmann, F. (2012). Modeling of diffusion-controlled drug delivery. *Journal of Controlled Release*, 161(2), 351–362.
- [20]. Ullah, F., Othman, M. B. H., Javed, F., Ahmad, Z., & Akil, H. M. (2015). Classification, processing and application of hydrogels: A review. *Materials Science and Engineering C*, 57, 414–433

